🇺🇸 FDA
Pipeline program

Doravirine

1439-066

Phase 2 small_molecule active

Quick answer

Doravirine for Human Immunodeficiency Virus (HIV) Infection is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Human Immunodeficiency Virus (HIV) Infection
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials